| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 418.76 | 6.8% | 0.8% |
| Total Income | 418.76 | 6.8% | 0.8% |
| Expenditure | 399.48 | 5.0% | 57.0% |
| PBT | 4.74 | 296.7% | 100.9% |
| Net Profit | 4.48 | 197.0% | 100.9% |
| OPM | 4.61% | 1.68pp | |
| NPM | 1.07% | 2.25pp | |
| EPS | 0.06 | 200.0% | 101.0% |
Integra LifeSciences Reports Q2 2026 Financial Results
29 Jul 2026 · 29 Jul, 3:51 pm
Summary
Integra LifeSciences reported second quarter 2026 revenues of $418.8 million, a modest increase of 0.8% on a reported basis and 0.7% organically year-over-year. The company saw a significant improvement in profitability, with GAAP earnings per diluted share at $0.06 compared to a loss of $(6.31) in the prior year, and adjusted earnings per diluted share rising to $0.56 from $0.45. Management is updating its reported revenue guidance range to $1.654 billion to $1.695 billion due to foreign exchange impacts but is reaffirming its full-year organic revenue growth and adjusted EPS guidance. Production has commenced at the Braintree facility, supporting the planned fourth-quarter relaunch of SurgiMend®.
Key Highlights
- 1
Second quarter revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year.
- 2
Second quarter GAAP earnings per diluted share were $0.06, compared to a loss of $(6.31) in the prior year.
- 3
Adjusted earnings per diluted share for the second quarter of 2026 were $0.56, an increase from $0.45 in the prior year.
- 4
The Company is updating its reported revenue guidance range to $1.654 billion to $1.695 billion to reflect the impact of a stronger U.S. dollar on foreign exchange rates.
- 5
The Company is reaffirming its 2026 full-year organic revenue growth guidance of 0.8% to 3.3% and adjusted earnings per share guidance of $2.40 to $2.50.
- 6
The Company initiated production at its Braintree manufacturing facility and remains on track for the planned fourth-quarter relaunch of SurgiMend®.
Management Comments
Stuart Essig
Our second-quarter performance reflects meaningful progress on our most important priorities. We are improving supply reliability, advancing quality, and returning products to market with discipline. The Braintree facility is now producing and ramping to support the planned SurgiMend relaunch later this year. At the same time, we are seeing the benefits of a more aligned commercial organization while we continue to reduce our balance sheet leverage. Supported by our broad portfolio, attractive markets, and focused leadership team, we are strengthening our operating foundation and enhancing our ability to deliver sustainable long-term shareholder value.
Informational and educational content only. Not investment advice.